Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb. Read this story
Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb. Read this story
More from BioSpace | Resume Careers Merck Launches Phase III Study for KRAS Hopeful Eyes Challenge to Amgen and BMS BioSpace advice Merck & Co. KRAS Pembrolizumab Non-small cell lung cancer Oncology Clinical trial